Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 147 entries
Sorted by: Best Match Show Resources per page
Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.

Lupus science & medicine

Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, Zhang J, Yu L, Rovin BH.
PMID: 26629350
Lupus Sci Med. 2015 Nov 18;2(1):e000112. doi: 10.1136/lupus-2015-000112. eCollection 2015.

INTRODUCTION: The kidney biopsy is used to diagnose and guide initial therapy in patients with lupus nephritis (LN). Kidney histology does not correlate well with clinical measurements of kidney injury or predict how patients will respond to standard-of-care immunosuppression....

Cite
Parikh SV, Malvar A, Song H, et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med. 2015;2(1):e000112doi: 10.1136/lupus-2015-000112.
Parikh, S. V., Malvar, A., Song, H., Alberton, V., Lococo, B., Vance, J., Zhang, J., Yu, L., & Rovin, B. H. (2015). Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus science & medicine, 2(1), e000112. https://doi.org/10.1136/lupus-2015-000112
Parikh, Samir V, et al. "Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders." Lupus science & medicine vol. 2,1 (2015): e000112. doi: https://doi.org/10.1136/lupus-2015-000112
Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, Zhang J, Yu L, Rovin BH. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med. 2015 Nov 18;2(1):e000112. doi: 10.1136/lupus-2015-000112. eCollection 2015. PMID: 26629350; PMCID: PMC4654163.
Copy Download .nbib Format: NLM
Promyelocytic sarcoma of the spine: a case report and review of the literature.

Advances in hematology

Pacilli L, Lo Coco F, Ramadan SM, Giannì L, Pingi A, Remotti D, Majolino I.
PMID: 20339529
Adv Hematol. 2010;2010:137608. doi: 10.1155/2010/137608. Epub 2010 Mar 18.

Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells. It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia. MS is extremely uncommon in acute...

Cite
Pacilli L, Lo Coco F, Ramadan SM, et al. Promyelocytic sarcoma of the spine: a case report and review of the literature. Adv Hematol. 2010;2010:137608doi: 10.1155/2010/137608.
Pacilli, L., Lo Coco, F., Ramadan, S. M., Giannì, L., Pingi, A., Remotti, D., & Majolino, I. (2010). Promyelocytic sarcoma of the spine: a case report and review of the literature. Advances in hematology, 2010137608. https://doi.org/10.1155/2010/137608
Pacilli, Leonardo, et al. "Promyelocytic sarcoma of the spine: a case report and review of the literature." Advances in hematology vol. 2010 (2010): 137608. doi: https://doi.org/10.1155/2010/137608
Pacilli L, Lo Coco F, Ramadan SM, Giannì L, Pingi A, Remotti D, Majolino I. Promyelocytic sarcoma of the spine: a case report and review of the literature. Adv Hematol. 2010;2010:137608. doi: 10.1155/2010/137608. Epub 2010 Mar 18. PMID: 20339529; PMCID: PMC2843861.
Copy Download .nbib Format: NLM
WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity.

Leukemia

Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G.
PMID: 20072158
Leukemia. 2010 Jan 14; doi: 10.1038/leu.2009.207. Epub 2010 Jan 14.

Core-binding factor (CBF) leukemias are characterized by a high degree of sensitivity to high-dose cytarabine (ARA-C) treatment and by a relatively favorable prognosis compared with most other forms of adult acute myeloid leukemia (AML). The molecular basis of the...

Cite
Cilloni D, Carturan S, Maffè C, et al. WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. Leukemia. 2010;doi: 10.1038/leu.2009.207.
Cilloni, D., Carturan, S., Maffè, C., Messa, F., Arruga, F., Messa, E., Pradotto, M., Pautasso, M., Zanone, C., Fornaciari, P., Defilippi, I., Rotolo, A., Greco, E., Iacobucci, I., Martinelli, G., Lo-Coco, F., Bracco, E., & Saglio, G. (2010). WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. Leukemia, . https://doi.org/10.1038/leu.2009.207
Cilloni, D, et al. "WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity." Leukemia vol. (2010). doi: https://doi.org/10.1038/leu.2009.207
Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G. WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. Leukemia. 2010 Jan 14; doi: 10.1038/leu.2009.207. Epub 2010 Jan 14. PMID: 20072158.
Copy Download .nbib Format: NLM
ED in APL: tip of the iceberg?.

Blood

Lo-Coco F.
PMID: 21816836
Blood. 2011 Aug 04;118(5):1188-9. doi: 10.1182/blood-2011-06-361238.

No abstract available.

Cite
Lo-Coco F. ED in APL: tip of the iceberg?. Blood. 2011;118(5):1188-9doi: 10.1182/blood-2011-06-361238.
Lo-Coco, F. (2011). ED in APL: tip of the iceberg?. Blood, 118(5), 1188-9. https://doi.org/10.1182/blood-2011-06-361238
Lo-Coco, Francesco. "ED in APL: tip of the iceberg?." Blood vol. 118,5 (2011): 1188-9. doi: https://doi.org/10.1182/blood-2011-06-361238
Lo-Coco F. ED in APL: tip of the iceberg?. Blood. 2011 Aug 04;118(5):1188-9. doi: 10.1182/blood-2011-06-361238. PMID: 21816836.
Copy Download .nbib Format: NLM
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

Blood cancer journal

Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, Pelicci PG.
PMID: 24658373
Blood Cancer J. 2014 Mar 21;4:e195. doi: 10.1038/bcj.2014.19.

No abstract available.

Cite
Riva L, Ronchini C, Bodini M, et al. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer J. 2014;4:e195doi: 10.1038/bcj.2014.19.
Riva, L., Ronchini, C., Bodini, M., Lo-Coco, F., Lavorgna, S., Ottone, T., Martinelli, G., Iacobucci, I., Tarella, C., Cignetti, A., Volorio, S., Bernard, L., Russo, A., Melloni, G. E., Luzi, L., Alcalay, M., Dellino, G. I., & Pelicci, P. G. (2014). Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood cancer journal, 4e195. https://doi.org/10.1038/bcj.2014.19
Riva, L, et al. "Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups." Blood cancer journal vol. 4 (2014): e195. doi: https://doi.org/10.1038/bcj.2014.19
Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, Pelicci PG. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer J. 2014 Mar 21;4:e195. doi: 10.1038/bcj.2014.19. PMID: 24658373; PMCID: PMC3972704.
Copy Download .nbib Format: NLM
High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment.

Journal of clinical medicine

Balestro E, Cocconcelli E, Giraudo C, Polverosi R, Biondini D, Lacedonia D, Bazzan E, Mazzai L, Rizzon G, Lococo S, Turato G, Tinè M, Cosio MG, Saetta M, Spagnolo P.
PMID: 31540181
J Clin Med. 2019 Sep 15;8(9). doi: 10.3390/jcm8091469.

Antifibrotic treatment slows down functional decline and disease progression in idiopathic pulmonary fibrosis (IPF). High-resolution computed tomography (HRCT) is useful to diagnose IPF; however, little is known about whether and to what extent HRCT changes reflect functional changes during...

Cite
Balestro E, Cocconcelli E, Giraudo C, et al. High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment. J Clin Med. 2019;8(9)doi: 10.3390/jcm8091469.
Balestro, E., Cocconcelli, E., Giraudo, C., Polverosi, R., Biondini, D., Lacedonia, D., Bazzan, E., Mazzai, L., Rizzon, G., Lococo, S., Turato, G., Tinè, M., Cosio, M. G., Saetta, M., & Spagnolo, P. (2019). High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment. Journal of clinical medicine, 8(9), . https://doi.org/10.3390/jcm8091469
Balestro, Elisabetta, et al. "High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment." Journal of clinical medicine vol. 8,9 (2019). doi: https://doi.org/10.3390/jcm8091469
Balestro E, Cocconcelli E, Giraudo C, Polverosi R, Biondini D, Lacedonia D, Bazzan E, Mazzai L, Rizzon G, Lococo S, Turato G, Tinè M, Cosio MG, Saetta M, Spagnolo P. High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment. J Clin Med. 2019 Sep 15;8(9). doi: 10.3390/jcm8091469. PMID: 31540181; PMCID: PMC6780456.
Copy Download .nbib Format: NLM
Clinical impact of .

Blood advances

Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM.
PMID: 29296827
Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26.

Although overexpression of the brain and acute leukemia, cytoplasmic (

Cite
Lucena-Araujo AR, Pereira-Martins DA, Koury LC, et al. Clinical impact of . Blood Adv. 2017;1(21):1807-1814doi: 10.1182/bloodadvances.2017005926.
Lucena-Araujo, A. R., Pereira-Martins, D. A., Koury, L. C., Franca-Neto, P. L., Coelho-Silva, J. L., de Deus Wagatsuma, V. M., Melo, R. A. M., Bittencourt, R., Pagnano, K., Pasquini, R., Chiattone, C. S., Fagundes, E. M., Chauffaille, M. L., Schrier, S. L., Tallman, M. S., Ribeiro, R. C., Grimwade, D., Ganser, A., Löwenberg, B., Lo-Coco, F., Sanz, M. A., Berliner, N., & Rego, E. M. (2017). Clinical impact of . Blood advances, 1(21), 1807-1814. https://doi.org/10.1182/bloodadvances.2017005926
Lucena-Araujo, Antonio R, et al. "Clinical impact of ." Blood advances vol. 1,21 (2017): 1807-1814. doi: https://doi.org/10.1182/bloodadvances.2017005926
Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM. Clinical impact of . Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26. PMID: 29296827; PMCID: PMC5728094.
Copy Download .nbib Format: NLM
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia.

Frontiers in oncology

Ocadlikova D, Lecciso M, Isidori A, Loscocco F, Visani G, Amadori S, Cavo M, Curti A.
PMID: 31649875
Front Oncol. 2019 Oct 09;9:1004. doi: 10.3389/fonc.2019.01004. eCollection 2019.

In solid tumors and hematological malignancies, including acute myeloid leukemia, some chemotherapeutic agents, such as anthracyclines, have proven to activate an immune response via dendritic cell-based cross-priming of anti-tumor T lymphocytes. This process, known as immunogenic cell death, is...

Cite
Ocadlikova D, Lecciso M, Isidori A, et al. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019;9:1004doi: 10.3389/fonc.2019.01004.
Ocadlikova, D., Lecciso, M., Isidori, A., Loscocco, F., Visani, G., Amadori, S., Cavo, M., & Curti, A. (2019). Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Frontiers in oncology, 91004. https://doi.org/10.3389/fonc.2019.01004
Ocadlikova, Darina, et al. "Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia." Frontiers in oncology vol. 9 (2019): 1004. doi: https://doi.org/10.3389/fonc.2019.01004
Ocadlikova D, Lecciso M, Isidori A, Loscocco F, Visani G, Amadori S, Cavo M, Curti A. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019 Oct 09;9:1004. doi: 10.3389/fonc.2019.01004. eCollection 2019. PMID: 31649875; PMCID: PMC6794495.
Copy Download .nbib Format: NLM
Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging.

Journal of thoracic disease

Guerrera F, Lococo F, Evangelista A, Rena O, Ampollini L, Vannucci J, Errico L, Lausi PO, Ventura L, Marchese V, Paci M, Filosso PL, Oliaro A, Casadio C, Puma F, Ruffini E, Ardissone F.
PMID: 30963001
J Thorac Dis. 2019 Feb;11(2):564-572. doi: 10.21037/jtd.2019.01.31.

BACKGROUND: In last years, an increasing interest emerges on the role of sub-lobar resection and lobe-specific lymph nodal dissection in the treatment of early-stage lung cancer. The aim of our study was to define the impact on cumulative incidence...

Cite
Guerrera F, Lococo F, Evangelista A, et al. Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging. J Thorac Dis. 2019;11(2):564-572doi: 10.21037/jtd.2019.01.31.
Guerrera, F., Lococo, F., Evangelista, A., Rena, O., Ampollini, L., Vannucci, J., Errico, L., Lausi, P. O., Ventura, L., Marchese, V., Paci, M., Filosso, P. L., Oliaro, A., Casadio, C., Puma, F., Ruffini, E., & Ardissone, F. (2019). Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging. Journal of thoracic disease, 11(2), 564-572. https://doi.org/10.21037/jtd.2019.01.31
Guerrera, Francesco, et al. "Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging." Journal of thoracic disease vol. 11,2 (2019): 564-572. doi: https://doi.org/10.21037/jtd.2019.01.31
Guerrera F, Lococo F, Evangelista A, Rena O, Ampollini L, Vannucci J, Errico L, Lausi PO, Ventura L, Marchese V, Paci M, Filosso PL, Oliaro A, Casadio C, Puma F, Ruffini E, Ardissone F. Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging. J Thorac Dis. 2019 Feb;11(2):564-572. doi: 10.21037/jtd.2019.01.31. PMID: 30963001; PMCID: PMC6409264.
Copy Download .nbib Format: NLM
The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia.

Frontiers in oncology

Ciciarello M, Corradi G, Loscocco F, Visani G, Monaco F, Cavo M, Curti A, Isidori A.
PMID: 31709192
Front Oncol. 2019 Oct 25;9:1135. doi: 10.3389/fonc.2019.01135. eCollection 2019.

Mesenchymal stromal cells (MSCs) have, for a long time, been recognized as pivotal contributors in the set up and maintenance of the hematopoietic stem cell (HSC) niche, as well as in the development and differentiation of the lympho-hematopoietic system....

Cite
Ciciarello M, Corradi G, Loscocco F, et al. The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Front Oncol. 2019;9:1135doi: 10.3389/fonc.2019.01135.
Ciciarello, M., Corradi, G., Loscocco, F., Visani, G., Monaco, F., Cavo, M., Curti, A., & Isidori, A. (2019). The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Frontiers in oncology, 91135. https://doi.org/10.3389/fonc.2019.01135
Ciciarello, Marilena, et al. "The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia." Frontiers in oncology vol. 9 (2019): 1135. doi: https://doi.org/10.3389/fonc.2019.01135
Ciciarello M, Corradi G, Loscocco F, Visani G, Monaco F, Cavo M, Curti A, Isidori A. The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Front Oncol. 2019 Oct 25;9:1135. doi: 10.3389/fonc.2019.01135. eCollection 2019. PMID: 31709192; PMCID: PMC6823864.
Copy Download .nbib Format: NLM
Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit.

Journal of thoracic disease

Carbonelli C, Rossi A, Ciliberti G, Grimaldi MA, Notarangelo S, Parente P, Copetti M, Zanforlin A, Lococo F, Taurchini M, Maiello E, De Cosmo S, Graziano P.
PMID: 34164185
J Thorac Dis. 2021 May;13(5):2942-2951. doi: 10.21037/jtd-20-2990.

BACKGROUND: There is a gap of knowledge about the factors that may determine the quality and the accuracy of diagnostic bronchoscopic procedures when setting up a new Interventional Pulmonology Unit. As little evidence-based medicine is available on this matter,...

Cite
Carbonelli C, Rossi A, Ciliberti G, et al. Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit. J Thorac Dis. 2021;13(5):2942-2951doi: 10.21037/jtd-20-2990.
Carbonelli, C., Rossi, A., Ciliberti, G., Grimaldi, M. A., Notarangelo, S., Parente, P., Copetti, M., Zanforlin, A., Lococo, F., Taurchini, M., Maiello, E., De Cosmo, S., & Graziano, P. (2021). Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit. Journal of thoracic disease, 13(5), 2942-2951. https://doi.org/10.21037/jtd-20-2990
Carbonelli, Cristiano, et al. "Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit." Journal of thoracic disease vol. 13,5 (2021): 2942-2951. doi: https://doi.org/10.21037/jtd-20-2990
Carbonelli C, Rossi A, Ciliberti G, Grimaldi MA, Notarangelo S, Parente P, Copetti M, Zanforlin A, Lococo F, Taurchini M, Maiello E, De Cosmo S, Graziano P. Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit. J Thorac Dis. 2021 May;13(5):2942-2951. doi: 10.21037/jtd-20-2990. PMID: 34164185; PMCID: PMC8182518.
Copy Download .nbib Format: NLM
Endoscopic and surgical treatment for bronchopleural fistula after major lung resection: an enduring challenge.

Journal of thoracic disease

Cusumano G, Alifano M, Lococo F.
PMID: 31245131
J Thorac Dis. 2019 May;11:S1351-S1356. doi: 10.21037/jtd.2019.03.102.

No abstract available.

Cite
Cusumano G, Alifano M, Lococo F. Endoscopic and surgical treatment for bronchopleural fistula after major lung resection: an enduring challenge. J Thorac Dis. 2019;11:S1351-S1356doi: 10.21037/jtd.2019.03.102.
Cusumano, G., Alifano, M., & Lococo, F. (2019). Endoscopic and surgical treatment for bronchopleural fistula after major lung resection: an enduring challenge. Journal of thoracic disease, 11S1351-S1356. https://doi.org/10.21037/jtd.2019.03.102
Cusumano, Giacomo, et al. "Endoscopic and surgical treatment for bronchopleural fistula after major lung resection: an enduring challenge." Journal of thoracic disease vol. 11 (2019): S1351-S1356. doi: https://doi.org/10.21037/jtd.2019.03.102
Cusumano G, Alifano M, Lococo F. Endoscopic and surgical treatment for bronchopleural fistula after major lung resection: an enduring challenge. J Thorac Dis. 2019 May;11:S1351-S1356. doi: 10.21037/jtd.2019.03.102. PMID: 31245131; PMCID: PMC6560590.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 147 entries